Neuroblastoma is a leading cause of cancer-related death in children. Accumulated data
suggest that differentiation arrest of the neural-crest-derived sympathoadrenal lineage …

Dysregulated expression of the transcription factor MYCN is frequently detected in nervous
system tumors such as childhood neuroblastoma. Here, gene amplification of MYCN is a …

Rapid protein degradation enables cells to quickly modulate protein abundance.
Dysregulation of short-lived proteins plays essential roles in disease pathogenesis. A …

Neuroblastoma is a pediatric malignancy with heterogeneous clinical outcomes. To better
understand neuroblastoma pathogenesis, here we analyze whole-genome, whole-exome …

The somatic mutations in each cancer genome are caused by multiple mutational
processes, each of which leaves a characteristic imprint (or 'signature'), potentially caused …

Amplification of MYCN is the driving oncogenic change in a subset of high-risk
neuroblastomas. The MYCN protein and the Aurora-A kinase form a complex during the S …

Telomere maintenance by telomerase activation or alternative lengthening of telomeres
(ALT) is a major determinant of poor outcome in neuroblastoma. Here, we screen for ALT in …

Simple Summary Since it was first described over two decades ago, the Alternative
Lengthening of Telomeres (ALT) pathway has been well accepted to hold clinical …

Neuroblastoma (NB) is a pediatric cancer of the sympathetic nervous system and one of the
most common solid tumors in infancy. Amplification of MYCN, copy number alterations …

Neuroblastoma has heterogenous clinical presentations that are reflected by several well-
defined clinical factors and biomarkers. Combinations of these clinical and biologic …